Sort
8,912 grants matching “sars cov 2”
Non-Human Primate Lymphoid Organ Chips for Vaccine Assessment
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2024 · AI
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2023 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2024 · AI
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2024 · AI
RFA-IP-22-001 - Burden and sequelae of influenza, SARS-CoV-2 and other respiratory viruses associated Severe Acute Respiratory Infections among Indian adult population aged 18-60yrs
$1,000,000Anand Krishnan · All-India Institute Of Medical Sciences · U01 · FY2022 · IP
Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Multisystem Inflammatory Syndrome in Children (MIS-C) long-term follow-up
$1,000,000Gina Montealegre · Leidos Biomedical Research, Inc. · N01 · FY2021 · AI
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
$1,000,000Emmanuel B Walter · Duke University · U01 · FY2023 · IP
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2025 · AI
Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure
$1,000,000Zachary A Bornholdt · Eitr Biologics, Inc. · R44 · FY2025 · AI
Supporting Patients Recovering from COVID-19 (SPaRC)
$1,000,000Ann Marie Parker · Johns Hopkins University · U18 · FY2024 · HS
FACILITIES THAT PRODUCE MEAT AND POULTRY PRODUCTS HAVE RECENTLY BEEN CLOSED BECAUSE WORKERS CONTRACTED COVID-19 AND WERE UNABLE TO WORK. THIS PUTS A STRAIN ON THE FOOD SUPPLY BY REDUCING THE AMOUNT OF MEAT AND POULTRY ON GROCERY STORE SHELVES. RESEARCH IS NECESSARY TO UNDERSTAND WHY SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, IS A PROBLEM IN MEAT AND POULTRY PROCESSING ENVIRONMENTS. IT IS BELIEVED THAT INFECTIONS WITH SARS-COV-2 VIRUS PRIMARILY OCCUR BY EXPOSURE TO DROPLETS IN THE AIR AND CONTAMINATED SURFACES. THEREFORE, INVESTIGATING THE CONDITIONS WITHIN MEAT AND POULTRY PROCESSING ENVIRONMENTS (E.G., LOW TEMPERATURES, HIGH HUMIDITY, INCREASED AIR MOVEMENT, WORKERS IN CLOSE PROXIMITY TO ONE ANOTHER) TO IDENTIFY AREAS AND SURFACES THAT ARE AT HIGH-RISK FOR CONTAMINATION AND SPREAD OF OF INFECTIOUS SARS-COV-2 VIRUS IS CRITICAL IN ORDER TO SOLVE THIS ISSUE. FINDING SOLUTIONS THAT WILL LIMIT THE EXPOSURE OF MEAT AND POULTRY PROCESSING EMPLOYEES WILL PROTECT THEIR HEALTH AND ENSURE CONSUMERS HAVE AN AMPLE SUPPLY OF MEAT AND POULTRY PRODUCTS AT THE GROCERY STORE. THE OVERALL GOAL OF OUR PROJECT IS TO REDUCE WORKER EXPOSURE TO SARS-COV-2 IN MEAT AND POULTRY PROCESSING ENVIRONMENTS. OUR TEAM WILL DO THIS BY 1) EVALUATING POTENTIAL SOURCES OF EXPOSURE (E.G. EQUIPMENT SURFACES, WORKER ATTIRE, MEAT AND PACKAGING MATERIALS) AND DETERMINING THE AMOUNT AND LONGEVITY OF INFECTIOUS SARS-COV-2 THAT IS PRESENT DURING AND AFTER MEAT PROCESSING AND PACKAGING ACTIVITIES, 2) IDENTIFYING, DEVELOPING, VALIDATING, AND DELIVERING PRACTICAL CLEANING AND DISINFECTION
$1,000,000Kansas State University · · FY2020 · National Institute of Food and Agriculture
SBIR Phase II: A Novel Host-Directed Broad-Spectrum Antiviral and Efficient Immunomodulatory Agent Against Coronaviruses: Lead Optimization Studies
$1,000,000Mohammad Noshi · Akanocure Pharmaceuticals, Inc. · · FY2024 · TIP
STTR Phase II: VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses
$1,000,000Stephanie Deshayes · Tempo Therapeutics · · FY2023 · TIP
PIPP Phase I: Advancing Environmental Surveillance for Pandemic Prediction in Remote and Resource Poor Settings
$1,000,000Scott Berry · University Of Kentucky Research Foundation · · FY2022 · CSE
PIPP Phase I: Develop and Evaluate Computational Frameworks to Predict and Prevent Future Coronavirus Pandemics
$1,000,000Hong Qin · University Of Tennessee Chattanooga · · FY2022 · CSE
STTR Phase II: Artificial Intelligence (AI)-based Development of Neutralizing Antibodies for SARS-CoV-2
$1,000,000Barry D Olafson · Protabit Llc · · FY2022 · TIP
CEIRR: SARS-CoV-2 Research Activities
$1,000,000Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2021 · AI
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Triple humanized ACE2-TMPRSS-FcGRT mouse models for COVID research in the C57BU6 and BALBIc backgrounds.
$1,000,000Kurt Jarnagin · Synbal, Inc. · R44 · FY2022 · AI
NHP Resources for SARS-CoV-2/COVID-19 Countermeasure Development
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2021 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2023 · AI
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine
$1,000,000Ellen Elizabeth Sparger · Tendel Therapies Inc. · R44 · FY2023 · AI
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
$999,998Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2025 · AI
Improved diagnostic sensitivity for rapid COVID-19 testing using Enhanced Preservation Media
$999,975Trevor Levin · Convergent Genomics, Inc. · R44 · FY2020 · CA
BPCA-PTN COVID-19 STUDIES
$999,956Md, Kanecia Zimmerman · Duke University · N01 · FY2022 · HD